[14C]-BGB-16673 for Healthy Subjects

Overseen By Study Director Study Director

Age: 18 - 65

Sex: Male

Trial Phase: Phase 1

Sponsor: BeiGene

Disqualifiers: Metabolic, Cardiovascular, Psychiatric, others

No Placebo Group All trial participants will receive the active study treatment (no placebo)

Compensation: Varies

Number of Visits: Unknown

Duration: 1 day

8 Participants Needed

Trial Summary

Will I have to stop taking my current medications?

The trial information does not specify whether you need to stop taking your current medications. However, since the study involves healthy participants and excludes those with significant medical conditions, it's likely that participants should not be on any regular medications.

What is the purpose of this trial?

The purpose of this study is to determine the absorption, metabolism, and excretion of \[14C\]-BGB-16673 and to characterize and determine, where possible, the metabolites present in plasma, urine, and feces in healthy male participants following a single oral administration.

Research Team

Study Director Study Director

Principal Investigator

BeiGene

Eligibility Criteria

This trial is for healthy men with a BMI between 18.0 and 32.0, who have at least one bowel movement daily, can understand and sign the consent form, and have no significant medical history findings.

Inclusion Criteria

I have at least one bowel movement daily.

I understand and agree to follow the study rules.

My BMI is between 18.0 and 32.0.

Timeline

Screening

Participants are screened for eligibility to participate in the trial

1-2 weeks

Treatment

Participants receive a single oral dose of [14C]-BGB-16673

1 day

Metabolism and Excretion Monitoring

Participants are monitored for absorption, metabolism, and excretion of the drug, with sample collection from plasma, urine, and feces

1-2 weeks

Follow-up

Participants are monitored for safety and effectiveness after treatment

2 weeks

Treatment Details

Interventions

• [14C]-BGB-16673

Trial Overview [14C]-BGB-16673 is being tested to see how it's absorbed, metabolized, and excreted after a single oral dose in healthy participants. The study will track this drug in blood, urine, and feces.

Participant Groups

Group I: Single Arm: [14C]-BGB-16673 Experimental Treatment 1 Intervention

Participants will receive a single dose of \[14C\]-BGB-16673

Who Is Running the Clinical Trial?

BeiGene

Lead Sponsor

Trials

216

Recruited

32,500+